ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
This feature about an attending preparing for her upcoming week of service offers a case vignette accompanied by two essays, one supporting visiting patients early…
Sudden cardiac death in children and young adults is a relatively rare but tragic event whose pathophysiology is unknown at the molecular level. Evidence indicates…
This is a resection of a popliteal artery aneurysm associated with a massive extremity arteriovenous malformation. Objectives:1. Describe the safe resection …
The new fiber-optic probe could transform aneurysm and brain clot treatments
Some cautioned against reading too much into this analysis, since the main trial did not meet its primary endpoint.
Implantable cardioverter-defibrillators last longer, and interest in reliable leads with targeted lead placement is growing. The OmniaSecureā¢ defibrillation lead is a novel small-diameter, catheter-delivered lead…
The Evolut valves posed difficulties for operators trying to access the coronaries, a potential problem for younger patients.
AbstractBackground and aims. Data describing the long-term efficacy, safety, and tolerability of inclisiran are limited. This was explored in ORION-8, an o
Nelson Shardey now faces a 10-year wait for “settlement” and a bill running into thousands of pounds.
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.